Shalby Ltd. · NSE:SHALBY
Shalby — Q1 FY2019 Earnings Presentation
19 slides from Shalby's earnings presentation, 2018
Slide 1: Investor Presentation
SHALBY MULTI-SPECIALTY —— HOSPITALS — @ Investor Presentation
Slide 2: Important Disclosure
Important Disclosure No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its da
Slide 3: Because passion drives perfection
…because passion drives perfection… …and perfection drives performance “ 3
Slide 4: Current Scale of Operations
Current Scale of Operations 11 Hospitals 52% Operating bed to total bed capacity 2,012* Total Bed Capacity 47% Bed Occupancy (based on census beds) 1,052 Operational beds 31% 11 year CAGR Revenue 887 Census Beds 40% 11 year CAGR EBITDA 165 Non Census Beds 390 Doctors & 3,500+ Support Staff Double-di
Slide 5: Performance Q1FY19
~ @ Performance Q1FY19
Slide 6: Key Developments of the Quarter
Key Developments of the Quarter Revenue growth of 31% Y-o-Y Launched Centre Avg. Occupied Beds rose by 57% and for Liver Disease and Transplant Y-o-YWide procedureEBITDA margin penetration – to Tier 2 and 3for the quarter cities stood at 23% 6
Slide 7: Performance Synopsis
Performance Synopsis (INR in million) Quarter Ended Quarter Ended Particulars % of Revenue % of Revenue Growth 30-06-18 30-06-17 Total Revenue 1,187.4 904.2 31.3% EBITDA 275 23.2% 255.8 28.3% 7.5% Bed Capacity (Nos.) 2012 2012 0% Operational Beds (Nos.) 1,102 841 31.0% Average Length of Stay 3.11 da
Slide 8: Financial Highlights Q1FY19 Standalone
Financial Highlights Q1FY19 Standalone (INR in million) Particulars Quarter Ended % of Revenue Quarter Ended % of Revenue Growth 30/06/2018 30/06/2017 Revenue from Operations 1,159.7 895.7 29.5% Other Income 27.7 8.5 Total Income 1,187.4 904.2 31.3% Expenses Materials & Consumables 298.2 25.1% 218.5
Slide 9: Financials Parameters
Financials Parameters (INR in million) Total Revenue EBITDA 275.0 PAT 121.3 1187.4 904.2 75.7 255.8 Q1 FY18 Q1 FY19 Q1 FY18 Q1 FY19 Q1 FY18 Q1 FY19 9
Slide 10: ARPOB and ALOS
ARPOB and ALOS 36,720 31,141 3.88 3.11 Q1 FY18 Q1 FY19 ARPOB (in Rs / day) ALOS (Days) Shrink in ARPOB is due to change in specialty mix due to increased multi-specialty focus. 10
Slide 11: Revenue Mix Q1FY19
Revenue Mix Q1FY19 Specialty Mix Payee Profile 3% 3% 10% 4% 10% 6% 48% 20% 12% 66% 9% 8% Arthroplasty Other Ortho Self Pay Corporate - Govt TPA Corporate - Private Critical Care & General Medicine Cardiac Science Oncology Nephrology Neurology Others 11
Slide 12: Surgery Count and Cost Structure Q1FY19
Surgery Count and Cost Structure Q1FY19 Cost Structure Surgery Count 77% 21% 2% 6% 17% 42% 4% 3% 2% 23% 4% 25% 6% Q1FY19 7% Total Operational Expenses 15% Advt & Promotion Administrative Expenses Arthroplasty Other Ortho Nephrology General Surgery Employee Costs Cardiac Science Neurology Oncology Ot
Slide 13: Bed Count Split
Bed Count Split 2,012 2,012 1052 841 419 267 Q1 FY18 Q1 FY19 Bed Capacity Operational Occupied 13
Slide 14: Maturity Profile – Q1 FY19
Maturity Profile – Q1 FY19 Avg. Operational Non- Non-Census Total Bed Maturity Profile Occupied Census Beds Beds Operational Beds Capacity Beds Beds 4 years + (SG; Vijay; 165 325 57 382 212 594 Krishna; Vapi) 2-4 years (Jabalpur, 143 309 52 361 115 476 Indore) < 2 years (Jaipur; Naroda; 111 583 892
Slide 15: Maturity Profile – Q1 FY19 – with Revenue mix
Maturity Profile – Q1 FY19 – with Revenue mix % of Total Maturity Profile Arthroplasty Non Arthroplasty ALOS Revenue 4 years + (SG; Vijay; 21% Krishna; Vapi) 52% 32% 3.34 2-4 years 4% 17% 3.78 (Jabalpur, Indore) 22% < 2 years (Jaipur; Naroda; 26% Surat; Mohali) 12% 14% 2.33 Total 48% 52% 3.11 15
Slide 16: Shareholding Pattern
Shareholding Pattern Shareholding as on 30th June 2018 0.94% 0.13% 0.37% 0.13% 0.06% 1.35% Promoter & Promoter Group 4.50% Resident Individuals & HUFs 5.88% Foreign Portfolio Investors 7.22% Bodies Corporate Alternative Investment Funds Employee Trusts Mutual Funds Non-Resident Indians/Foreign natio
Slide 17: Our Strengths and Differentiators
Our Strengths and Differentiators Strong brand, Increasing focus Experienced global Optimized on Quaternary promoters with leadership in Business Model treatments such hands-on Joint now being as Oncology and involvement Replacement replicated Organ transplants Even after the Strong emphasis Leaders
Slide 18: Detailed Information
Detailed Information For more detailed information please click on the link below: • Q1FY19 result • Monitoring Agency Report for IPO proceeds • FY18 result 18
Slide 19: Thank you
Thank you Opp. Karnavati Club, S G Road, Ahmedabad – 380015, Gujarat, India